Dermatomyositis (DM) and polymyositis (PM) represent a group of chronic inflammatory
disorders characterised by myogenic changes, skin eruptions or both. Clinical features
are heterogeneous, with various degrees of skin manifestations, myositis, pulmonary
involvement and malignancy risk; in combination, they determine the severity and prognosis
of the disease. Although the cause of these disorders remains unclear, autoimmunity
is considered to play a critical role due to the presence of diagnostic autoantibodies,
known as myositis-specific autoantibodies (MSAs). In Japan, an enzyme-linked immunosorbent
assay (ELISA) system for detecting five anti-ARS antibodies simultaneously, including
anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ and anti-KS antibodies, was developed and
obtained regulatory diagnostic approval in 2014. We also developed ELISA systems that
obtained regulatory approval in 2016 to detect anti-Mi-2, anti-MDA5 and anti-TIF1γ
antibodies and conducted a multi-centre study to examine their clinical utility as
previously described [
[1]
,
[2]
]. Completing the study also enabled us to directly compare the clinical features
of these four MSAs in Japanese adult patients with PM/DM. We confirmed their characteristics
and proposed the heterogeneity by showing the different distributions of serum creatine
kinase (CK) levels among the four groups.- Fujimoto M.
- Murakami A.
- Kurei S.
- Okiyama N.
- Kawakami A.
- Mishima M.
- Sato S.
- Seishima M.
- Suda T.
- Mimori T.
- Takehara K.
- Kuwana M.
Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary
factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
J. Dermatol. Sci. 2016; 84: 272-281
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Dermatological ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies.PLoS One. 2016; 11e0154285
- Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.J. Dermatol. Sci. 2016; 84: 272-281
- RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease.Arthritis Rheum. 2009; 60: 2193-2200
- Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.Rheumatology (Oxford). 2010; 49: 1726-1733
- Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study.Arch. Dermatol. 2011; 147: 391-398
- Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody.Arthritis Care Res. (Hoboken). 2012; 64: 1602-1610
- Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.Arthritis Care Res. (Hoboken). 2013; 65: 1316-1324
- The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.J. Am. Acad. Dermatol. 2011; 65: 25-34
- A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.Medicine (Baltimore). 1991; 70: 360-374
- Classification of idiopathic inflammatory myopathies: pathology perspectives.Curr. Opin. Neurol. 2019; 32: 704-714
Article info
Publication history
Published online: May 25, 2021
Accepted:
May 23,
2021
Received in revised form:
May 21,
2021
Received:
April 28,
2021
Identification
Copyright
© 2021 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.
